Canopus BioPharma to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference in Monte Carlo

  
    
  
  
    
      Canopus BioPharma, Inc. (OTCPK: CBIA), a biotechnology company 
      developing pharmaceutical products and assay methods for patients 
      suffering from infectious disease, radiation sickness, cancer, and 
      addiction, announced today that it will present at the Rodman & Renshaw 
      5th Annual Global Healthcare Conference in Monte Carlo, Monaco on 
      Monday, May 19, at 4:25 AM Eastern (10:25 AM Central European Summer 
      Time).
    
    
      Patrick Prendergast, Chief Executive Officer of Canopus BioPharma, will 
      be presenting on behalf of the Company. Also in attendance will be Len 
      Rothstein, President, and Leo Prendergast, Chief Operating Officer. For 
      those unable to attend the event, the Canopus BioPharma presentation is 
      being webcast and can be accessed live or in replay format for a limited 
      time at the following link: http://www.wsw.com/webcast/rrshq13/cbia.pk.
    
    
      Presentations by more than 175 emerging growth biotechnology companies 
      are expected Rodman & Renshaw 5th Annual Global Healthcare Conference 
      that rapidly has become the premier international event on the Life 
      Sciences calendar. Companies will share their accomplishments on an 
      array of therapeutic topics including oncology, cardiovascular disease, 
      central nervous system disorders, infectious diseases and medical device 
      technology. The event will unite companies with institutional investors, 
      venture capitalists, senior corporate executives and experts from the 
      scientific and medical communities. The Conference will include company 
      presentations, breakout sessions, and one-on-one meetings with 
      presenting companies.
    
    
      About Rodman & Renshaw:
    
    
      Rodman & Renshaw is a full-service investment bank dedicated to 
      providing investment banking services to companies that have significant 
      recurring capital needs due to their growth and development strategies. 
      We also provide research and sales and trading services to institutional 
      investor clients that focus on such companies. Since 2003, Rodman has 
      been a leading investment banking firm to the biotechnology sector, a 
      capital intensive market segment, as well as a leader in the PIPE 
      (private investment in public equity) and RD (registered direct 
      placements) transaction markets.
    
    
      About Canopus BioPharma, Inc.:
    
    
      Canopus BioPharma, Inc. (OTCBB: CBIA) is dedicated to providing the 
      safest, most cost effective and efficacious pharmaceutical products and 
      assay methods in the areas of infectious disease, radiation protection, 
      cancer, and addiction. With innovative science, proven research and 
      development leadership, and superior products and compounds, Canopus 
      BioPharma has, since 2001, been committed to becoming a market trend 
      setter in a new era of healthcare. In addition, the Company is a world 
      leader in the development of novel camelid antibody products to provide 
      unique avenues of progress and improvement in assay methods and 
      monitoring capabilities for physicians, patients and researchers, 
      initially for food chain protection applications. Canopus maintains 
      staff in Australia, South Africa, Ireland, Panama and the USA. 
      Additional information on the Company is available at www.canopusbiopharma.com.
    
    
      Additional information on CB1400 is available from Canopus BioPharma 
      upon request from the contacts listed below on this press release.
    
    
      With the exception of historical information contained in this press 
      release, content herein may contain “forward 
      looking statements” that are made pursuant to 
      the Safe Harbor Provisions of the Private Securities Litigation Reform 
      Act of 1995. These statements are based on management’s 
      current expectations and are subject to uncertainty and changes in 
      circumstances. In particular, the Company may not be successful in its 
      efforts commercialize or attain acceptable clinical results for its 
      products. Investors are cautioned that forward-looking statements 
      involve risks and uncertainties that could cause actual results to 
      differ materially from the statements made. These factors include 
      general economic conditions, delays and risks associated with the 
      performance of contracts and research and development programs, 
      uncertainties as a result of research and development, consumer and 
      industry acceptance, litigation and/or court proceedings, regulatory 
      risks including approval of Food and Drug Administration filings, the 
      ability to achieve and maintain revenues and profitability in the Company’s 
      business lines, and other factors discussed in the Company's filings 
      with the Securities and Exchange Commission.